Actinic keratoses - a systemic review

Mainly elderly people with pale skin are affected by actinic keratoses (AK). Due to the demographic change, the prevalence of AK increased over the last years. An established risk factor is chronic UV-exposure (outdoor workers) inducing mutations of the tumor suppressor gene TP53 and the oncogene H-Ras. This leads to an intraepidermal proliferation of atypical keratinocytes. The term “field cancerization” characterises the presentation of multiple AK in UV-exposed areas. AK are also termed squamous cell carcinoma (SCC) in situ. The risk for AK turning into a SCC is 6-10%. In order to avoid invasive growth, an early treatment is recommended. During the last years multiple therapeutic options have been established. Depending on the clinical extent, lesion- or field-directed therapies with excellent clinical response and cosmetic results are available

Anti-Interleukin-5-Therapie bei eosinophilen Erkrankungen

Zusammenfassung: Bei einer Reihe von Erkrankungen, die durch eine Eosinophilie charakterisiert sind, findet man erhöhte Spiegel von Interleukin- (IL-)5 im Blut und/oder Gewebe. IL-5 spielt eine wichtige Rolle in der Regulierung von Produktion, Differenzierung, Rekrutierung, Aktivierung und Überleben eosinophiler Granulozyten. Daher stellt die Neutralisation von IL-5 durch blockierende Antikörper einen vielversprechenden neuen Ansatz in der Therapie dieser Erkrankungen dar. Erste klinische Studien zeigten, dass es nach Applikation von Anti-IL-5-Antikörpern zu einem raschen Abfall der Eosinophilenzahlen im peripheren Blut kommt. Eine Abnahme der Beschwerden wurde bei der lymphozytären Form hypereosinophiler Syndrome, bei eosinophiler Ösophagitis und bei chronischer Rhinitis mit nasaler Polyposis beobachtet. Im Gegensatz dazu zeigte eine Anti-IL-5-Antikörper-Behandlung von Patienten mit Asthma bronchiale oder mit atopischem Ekzem nicht den erwarteten klinischen Effekt. Zukünftige Studien werden zeigen, bei welchen eosinophilen Erkrankungen eine Anti-IL-5-Therapie wirksam ist und welche Patientengruppen auf diese Therapie anspreche

Актинический кератоз - обзор литературы

Mainly elderly people with pale skin are affected by actinic keratoses (AK). Due to the demographic change, the prevalence of AK increased over the last years. An established risk factor is chronic UV-exposure (outdoor workers) inducing mutations of the tumor suppressor gene TP53 and the oncogene H-Ras. This leads to an intraepidermal proliferation of atypical keratinocytes. The term field cancerization characterises the presentation of multiple AK in UV-exposed areas. AK are also termed squamous cell carcinoma (SCC) in situ. The risk for AK turning into a SCC is 6-10%. In order to avoid invasive growth, an early treatment is recommended. During the last years multiple therapeutic options have been established. Depending on the clinical extent, lesion- or field-directed therapies with excellent clinical response and cosmetic results are available.Актиническому кератозу (АК) в основном подвержены пожилые люди со светлой кожей. За последние годы в связи с демографическими изменениями увеличилась распространенность АК. установленным фактором риска, приводящим к возникновению мутаций в антионкогене TP53 и онкогене H-Ras, является хроническое ультрафиолетовое воздействие (работа на открытом воздухе), которое способствует внутриэпидермальной пролиферации атипичных кератиноцитов. термин поле канцеризации характеризуется наличием множественного АК в участках, подверженных УФ-облучению. также АК называется преинвазивной плоскоклеточной карциномой или плоскоклеточной карциномой in situ. Риск превращения АК в плоскоклеточную карциному составляет 6-10%. Во избежание инвазивного роста рекомендуется лечение на ранних стадиях. За последние годы были разработаны различные варианты терапевтического лечения. В зависимости от степени выраженности признаков существуют методы терапии, направленные на поврежденные участки и дающие превосходные косметические и клинические результаты

European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 1: treatment delivery and established indications – actinic keratoses, Bowen''s disease and basal cell carcinomas

Topical photodynamic therapy (PDT) is a widely approved therapy for actinic keratoses, Bowen''s disease (squamous cell carcinoma in situ), superficial and certain thin basal cell carcinomas. Recurrence rates when standard treatment protocols are used are typically equivalent to existing therapies, although inferior to surgery for nodular basal cell carcinoma. PDT can be used both as lesional and field therapies and has the potential to delay/reduce the development of new lesions. A protocol using daylight to treat actinic keratoses is widely practised, with conventional PDT using a red light after typically a 3-h period of occlusion employed for other superficial skin cancer indications as well as for actinic keratoses when daylight therapy is not feasible. PDT is a well-tolerated therapy although discomfort associated with conventional protocol may require pain-reduction measures. PDT using daylight is associated with no or minimal pain and preferred by patient. There is an emerging literature on enhancing conventional PDT protocols or combined PDT with another treatment to increase response rates. This guideline, published over two parts, considers all current approved and emerging indications for the use of topical PDT in dermatology, prepared by the PDT subgroup of the European Dermatology Forum guidelines committee. It presents consensual expert recommendations reflecting current published evidence

Antigen-Presenting Activity of Non-Langerhans Epidermal Cells in Contact Hypersensitivity Reactions

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/72263/1/j.1365-3083.1990.tb02914.x.pd